Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer

Venkatrao Vantaku, Sri Ramya Donepudi, Chandrashekar R. Ambati, Feng Jin, Vasanta Putluri, Khoa Nguyen, Kimal Rajapakshe, Cristian Coarfa, Venkata Lokesh Battula, Yair Lotan, Nagireddy Putluri

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

High-grade Bladder Cancer (BLCA) represents the most aggressive and treatmentresistant cancer that renders the patients with poor survival. However, only a few biomarkers have been identified for the detection and treatment of BLCA. Recent studies show that ganglioside GD2 can be used as cancer biomarker and/or therapeutic target for various cancers. Despite its potential relevance in cancer diagnosis and therapeutics, the role of GD2 is unknown in BLCA. Here, we report for the first time that high-grade BLCA tissues and cell lines have higher expression of GD2 compared to low-grade by high-resolution Mass Spectrometry. The muscle invasive UMUC3 cell line showed high GD2, mesenchymal phenotype, and cell proliferation. Besides, we have shown the cancer stem cells (CSC) property (CD44hiCD24lo) of GD2+ UMUC3 and J82 cells. Also, the evaluation of lipid metabolism in GD2+ BLCA cell lines revealed higher levels of Phosphatidylinositol (PI), Phosphatidic acid (PA), Cardiolipin (CL) and lower levels of Phosphatidylserine (PS), plasmenyl-phosphatidylethanolamines (pPE), plasmenyl-phosphocholines (pPC), sphingomyelins (SM), triglycerides (TGs) and N-Acetylneuraminic acid. These findings are significantly correlated with the tissues of BLCA patients. Based on this evidence, we propose that GD2 may be used as an effective diagnostic and therapeutic target for aggressive BLCA.

Original languageEnglish (US)
Pages (from-to)95620-95631
Number of pages12
JournalOncotarget
Volume8
Issue number56
DOIs
StatePublished - 2017

Fingerprint

Lipid Metabolism
Urinary Bladder Neoplasms
Phenotype
Cell Line
Phosphatidylethanolamines
Neoplasms
Phosphatidic Acids
Cardiolipins
Phosphorylcholine
Sphingomyelins
Neoplastic Stem Cells
Phosphatidylserines
N-Acetylneuraminic Acid
Therapeutics
Tumor Biomarkers
Phosphatidylinositols
GD2 ganglioside
Mass Spectrometry
Triglycerides
Biomarkers

Keywords

  • Bladder cancer
  • EMT
  • Ganglioside GD2
  • Lipid metabolism

ASJC Scopus subject areas

  • Oncology

Cite this

Vantaku, V., Donepudi, S. R., Ambati, C. R., Jin, F., Putluri, V., Nguyen, K., ... Putluri, N. (2017). Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. Oncotarget, 8(56), 95620-95631. https://doi.org/10.18632/oncotarget.21038

Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. / Vantaku, Venkatrao; Donepudi, Sri Ramya; Ambati, Chandrashekar R.; Jin, Feng; Putluri, Vasanta; Nguyen, Khoa; Rajapakshe, Kimal; Coarfa, Cristian; Battula, Venkata Lokesh; Lotan, Yair; Putluri, Nagireddy.

In: Oncotarget, Vol. 8, No. 56, 2017, p. 95620-95631.

Research output: Contribution to journalArticle

Vantaku, V, Donepudi, SR, Ambati, CR, Jin, F, Putluri, V, Nguyen, K, Rajapakshe, K, Coarfa, C, Battula, VL, Lotan, Y & Putluri, N 2017, 'Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer', Oncotarget, vol. 8, no. 56, pp. 95620-95631. https://doi.org/10.18632/oncotarget.21038
Vantaku, Venkatrao ; Donepudi, Sri Ramya ; Ambati, Chandrashekar R. ; Jin, Feng ; Putluri, Vasanta ; Nguyen, Khoa ; Rajapakshe, Kimal ; Coarfa, Cristian ; Battula, Venkata Lokesh ; Lotan, Yair ; Putluri, Nagireddy. / Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. In: Oncotarget. 2017 ; Vol. 8, No. 56. pp. 95620-95631.
@article{ac3438f07a284a658455f18de0384b78,
title = "Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer",
abstract = "High-grade Bladder Cancer (BLCA) represents the most aggressive and treatmentresistant cancer that renders the patients with poor survival. However, only a few biomarkers have been identified for the detection and treatment of BLCA. Recent studies show that ganglioside GD2 can be used as cancer biomarker and/or therapeutic target for various cancers. Despite its potential relevance in cancer diagnosis and therapeutics, the role of GD2 is unknown in BLCA. Here, we report for the first time that high-grade BLCA tissues and cell lines have higher expression of GD2 compared to low-grade by high-resolution Mass Spectrometry. The muscle invasive UMUC3 cell line showed high GD2, mesenchymal phenotype, and cell proliferation. Besides, we have shown the cancer stem cells (CSC) property (CD44hiCD24lo) of GD2+ UMUC3 and J82 cells. Also, the evaluation of lipid metabolism in GD2+ BLCA cell lines revealed higher levels of Phosphatidylinositol (PI), Phosphatidic acid (PA), Cardiolipin (CL) and lower levels of Phosphatidylserine (PS), plasmenyl-phosphatidylethanolamines (pPE), plasmenyl-phosphocholines (pPC), sphingomyelins (SM), triglycerides (TGs) and N-Acetylneuraminic acid. These findings are significantly correlated with the tissues of BLCA patients. Based on this evidence, we propose that GD2 may be used as an effective diagnostic and therapeutic target for aggressive BLCA.",
keywords = "Bladder cancer, EMT, Ganglioside GD2, Lipid metabolism",
author = "Venkatrao Vantaku and Donepudi, {Sri Ramya} and Ambati, {Chandrashekar R.} and Feng Jin and Vasanta Putluri and Khoa Nguyen and Kimal Rajapakshe and Cristian Coarfa and Battula, {Venkata Lokesh} and Yair Lotan and Nagireddy Putluri",
year = "2017",
doi = "10.18632/oncotarget.21038",
language = "English (US)",
volume = "8",
pages = "95620--95631",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "56",

}

TY - JOUR

T1 - Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer

AU - Vantaku, Venkatrao

AU - Donepudi, Sri Ramya

AU - Ambati, Chandrashekar R.

AU - Jin, Feng

AU - Putluri, Vasanta

AU - Nguyen, Khoa

AU - Rajapakshe, Kimal

AU - Coarfa, Cristian

AU - Battula, Venkata Lokesh

AU - Lotan, Yair

AU - Putluri, Nagireddy

PY - 2017

Y1 - 2017

N2 - High-grade Bladder Cancer (BLCA) represents the most aggressive and treatmentresistant cancer that renders the patients with poor survival. However, only a few biomarkers have been identified for the detection and treatment of BLCA. Recent studies show that ganglioside GD2 can be used as cancer biomarker and/or therapeutic target for various cancers. Despite its potential relevance in cancer diagnosis and therapeutics, the role of GD2 is unknown in BLCA. Here, we report for the first time that high-grade BLCA tissues and cell lines have higher expression of GD2 compared to low-grade by high-resolution Mass Spectrometry. The muscle invasive UMUC3 cell line showed high GD2, mesenchymal phenotype, and cell proliferation. Besides, we have shown the cancer stem cells (CSC) property (CD44hiCD24lo) of GD2+ UMUC3 and J82 cells. Also, the evaluation of lipid metabolism in GD2+ BLCA cell lines revealed higher levels of Phosphatidylinositol (PI), Phosphatidic acid (PA), Cardiolipin (CL) and lower levels of Phosphatidylserine (PS), plasmenyl-phosphatidylethanolamines (pPE), plasmenyl-phosphocholines (pPC), sphingomyelins (SM), triglycerides (TGs) and N-Acetylneuraminic acid. These findings are significantly correlated with the tissues of BLCA patients. Based on this evidence, we propose that GD2 may be used as an effective diagnostic and therapeutic target for aggressive BLCA.

AB - High-grade Bladder Cancer (BLCA) represents the most aggressive and treatmentresistant cancer that renders the patients with poor survival. However, only a few biomarkers have been identified for the detection and treatment of BLCA. Recent studies show that ganglioside GD2 can be used as cancer biomarker and/or therapeutic target for various cancers. Despite its potential relevance in cancer diagnosis and therapeutics, the role of GD2 is unknown in BLCA. Here, we report for the first time that high-grade BLCA tissues and cell lines have higher expression of GD2 compared to low-grade by high-resolution Mass Spectrometry. The muscle invasive UMUC3 cell line showed high GD2, mesenchymal phenotype, and cell proliferation. Besides, we have shown the cancer stem cells (CSC) property (CD44hiCD24lo) of GD2+ UMUC3 and J82 cells. Also, the evaluation of lipid metabolism in GD2+ BLCA cell lines revealed higher levels of Phosphatidylinositol (PI), Phosphatidic acid (PA), Cardiolipin (CL) and lower levels of Phosphatidylserine (PS), plasmenyl-phosphatidylethanolamines (pPE), plasmenyl-phosphocholines (pPC), sphingomyelins (SM), triglycerides (TGs) and N-Acetylneuraminic acid. These findings are significantly correlated with the tissues of BLCA patients. Based on this evidence, we propose that GD2 may be used as an effective diagnostic and therapeutic target for aggressive BLCA.

KW - Bladder cancer

KW - EMT

KW - Ganglioside GD2

KW - Lipid metabolism

UR - http://www.scopus.com/inward/record.url?scp=85033389050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033389050&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.21038

DO - 10.18632/oncotarget.21038

M3 - Article

VL - 8

SP - 95620

EP - 95631

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 56

ER -